These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22640567)

  • 1. Should risky treatments be reserved for secondary prevention? Theoretical considerations regarding risk-benefit tradeoffs.
    Westover MB; Eiseman NA; Bianchi MT
    J Clin Epidemiol; 2012 Aug; 65(8):877-86. PubMed ID: 22640567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Endemia of arterial hypertension in Russia and new approaches to its prevention].
    Volkov VS; Poseliugina OB; Nilova SA; Rokkina SA; Kirilenko NP; Sibilieva SV; Gnatenko EP
    Klin Med (Mosk); 2009; 87(1):70-2. PubMed ID: 19256267
    [No Abstract]   [Full Text] [Related]  

  • 3. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients.
    Stam-Slob MC; Visseren FL; Wouter Jukema J; van der Graaf Y; Poulter NR; Gupta A; Sattar N; Macfarlane PW; Kearney PM; de Craen AJ; Trompet S
    Clin Res Cardiol; 2017 Jan; 106(1):58-68. PubMed ID: 27554244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin in the treatment and prevention of cardiovascular disease: past and current perspectives and future directions.
    Hennekens CH; Dalen JE
    Am J Med; 2013 May; 126(5):373-8. PubMed ID: 23499330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin use following intracerebral hemorrhage: a decision analysis.
    Westover MB; Bianchi MT; Eckman MH; Greenberg SM
    Arch Neurol; 2011 May; 68(5):573-9. PubMed ID: 21220650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin in Older Adults: Need for Wider Utilization in Secondary Prevention and Individual Clinical Judgments in Primary Prevention.
    Sehgal M; Wood SK; Ouslander JG; Hennekens CH
    J Cardiovasc Pharmacol Ther; 2017 Nov; 22(6):511-513. PubMed ID: 28279072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis.
    Vegter S; Oosterhof P; van Boven JF; Stuurman-Bieze AG; Hiddink EG; Postma MJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):722-32. PubMed ID: 24967525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients--a longitudinal observational study.
    Leung WY; So WY; Stewart D; Lui A; Tong PC; Ko GT; Kong AP; Ma RC; Chan FK; Yang X; Chiang SC; Chan JC
    Cardiovasc Diabetol; 2009 Oct; 8():57. PubMed ID: 19878541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment.
    Mora S; Manson JE
    JAMA Intern Med; 2016 Aug; 176(8):1195-204. PubMed ID: 27322595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin for Primary and Secondary Prevention of Cardiovascular Disease.
    Godley RW; Hernandez-Vila E
    Tex Heart Inst J; 2016 Aug; 43(4):318-9. PubMed ID: 27547141
    [No Abstract]   [Full Text] [Related]  

  • 11. Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events.
    Bavry AA; Elgendy IY; Elbez Y; Mahmoud AN; Sorbets E; Steg PG; Bhatt DL;
    Clin Cardiol; 2017 Sep; 40(9):732-739. PubMed ID: 28520215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Primary and secondary prevention of ischemic stroke].
    Awada A
    J Med Liban; 2011; 59(4):213-9. PubMed ID: 22746010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improve the prevention of sudden cardiac arrest in emerging countries: the Improve SCA clinical study design.
    Zhang S; Singh B; Rodriguez DA; Chasnoits AR; Hussin A; Ching CK; Huang D; Liu YB; Cerkvenik J; Willey S; Kim YH
    Europace; 2015 Nov; 17(11):1720-6. PubMed ID: 26037794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized medicine and stroke prevention: where are we?
    Kim J; Thrift AG; Nelson MR; Bladin CF; Cadilhac DA
    Vasc Health Risk Manag; 2015; 11():601-11. PubMed ID: 26664130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meditation and Cardiovascular Risk Reduction: A Scientific Statement From the American Heart Association.
    Levine GN; Lange RA; Bairey-Merz CN; Davidson RJ; Jamerson K; Mehta PK; Michos ED; Norris K; Ray IB; Saban KL; Shah T; Stein R; Smith SC;
    J Am Heart Assoc; 2017 Sep; 6(10):. PubMed ID: 28963100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
    Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer.
    Puhan MA; Yu T; Stegeman I; Varadhan R; Singh S; Boyd CM
    BMC Med; 2015 Oct; 13():250. PubMed ID: 26423305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
    Dehmer SP; Maciosek MV; Flottemesch TJ; LaFrance AB; Whitlock EP
    Ann Intern Med; 2016 Jun; 164(12):777-86. PubMed ID: 27064573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
    Hill G; Barron R; Fust K; Skornicki ME; Taylor DC; Weinstein MC; Lyman GH
    J Med Econ; 2014 Jan; 17(1):32-42. PubMed ID: 24028444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.